All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-09-19T11:27:58.000Z

How can we intervene with MRD-directed therapy within and outside of transplantation?

Sep 19, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute myeloid leukemia.

During a meeting of the AML Hub Steering Committee, held on May 8, 2024, Jeffrey Lancet chaired a discussion on the question: How can we intervene with measurable residual disease (MRD)-directed therapy within and outside of transplantation? This featured contributions from Charles Craddock, Gail Roboz, and Yasushi Miyazaki. 

Lancet discusses the use of MRD-directed therapy, particularly in patients with MRD-positive disease, and the strategies for those transitioning from MRD positivity to negativity. The discussion includes insights from the QUAZAR study and raises concerns about the reliability of measuring MRD conversion, especially with flow cytometry. Risk stratification at diagnosis was also addressed, focusing on countries where MRD assessment for AML is not well established. The steering committee members recognize the unmet need to establish MRD as a definitive endpoint in clinical trials and to research the optimal timing for post-transplant MRD assessment. 

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
7 votes - 37 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox